Skip to main content

Welkom bij THIM Hogeschool voor Fysiotherapie & Bohn Stafleu van Loghum

THIM Hogeschool voor Fysiotherapie heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen. Je kunt je links eenvoudig registreren. Met deze gegevens kun je thuis, of waar ook ter wereld toegang krijgen tot Mijn BSL. Heb je een vraag, neem dan contact op met helpdesk@thim.nl.

Registreer

Om ook buiten de locaties van THIM, thuis bijvoorbeeld, van Mijn BSL gebruik te kunnen maken, moet je jezelf eenmalig registreren. Dit kan alleen vanaf een computer op een van de locaties van THIM.

Eenmaal geregistreerd kun je thuis of waar ook ter wereld onbeperkt toegang krijgen tot Mijn BSL.

Login

Als u al geregistreerd bent, hoeft u alleen maar in te loggen om onbeperkt toegang te krijgen tot Mijn BSL.

Top
Gepubliceerd in:

01-10-2010 | Original article

One-year clinical follow-up of a registry evaluating a percutaneous revascularisation strategy combining a pre-specified simple selection process with the use of a new thin-strut bare cobalt-chromium stent

Auteurs: P. R. Stella, G. Pavlakis, P. Agostoni, H. M. Nathoe, S. Hoseyni Guyomi, B. J. Hamer, T. X. Wildbergh, P. A. Doevendans, E. Van Belle

Gepubliceerd in: Netherlands Heart Journal | Uitgave 10/2010

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Extract

Percutaneous coronary interventions (PCI) are a valuable addition to treatment regimens in modern cardiology.1-3 The use of intracoronary metallic stents has improved results over balloon dilatation alone and has become standard care for patients undergoing PCI.4 However, in-stent restenosis, leading to recurrence of symptoms, has been the major drawback of bare metal stents (BMS).5 Drug-eluting stents (DES) were introduced in an attempt to overcome this problem and, due to the improved effectiveness in preventing restenosis, DES implantation has rapidly grown to up to 80% of cases in some countries.6 However, recently there have been concerns about their long-term safety,7 due to an increase in late stent thrombosis, possibly linked to delayed endothelialisation of the stent struts. Delayed endothelial cell growth is due to a non-selective inhibitory action of the drug on targeting both smooth muscle cell proliferation and endothelial cell regeneration.8 Moreover, DES definitely increases the cost of PCI when compared with BMS and debate is ongoing over the long-term cost-effectiveness of these devices.9
Literatuur
1.
go back to reference Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13-20. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13-20.
2.
go back to reference Schomig A, Mehilli J, de Waha A, Seyfarth M, Pache J, Kastrati A. A meta-analysis of 17 randomized trials of percutaneous coronary intervention-based strategy in patients with stable coronary artery disease. J Am Coll Cardiol. 2008;52:894-904. Schomig A, Mehilli J, de Waha A, Seyfarth M, Pache J, Kastrati A. A meta-analysis of 17 randomized trials of percutaneous coronary intervention-based strategy in patients with stable coronary artery disease. J Am Coll Cardiol. 2008;52:894-904.
3.
go back to reference Biondi-Zoccai G, Abbate A, Agostoni P, Testa L, Burzotta F, Lotrionte et al. Long-term benefits of an early invasive management in acute coronary syndromes depend on intra-coronary stenting and aggressive anti-platelet treatment: a meta-regression. Am Heart J. 2005;149:504-11. Biondi-Zoccai G, Abbate A, Agostoni P, Testa L, Burzotta F, Lotrionte et al. Long-term benefits of an early invasive management in acute coronary syndromes depend on intra-coronary stenting and aggressive anti-platelet treatment: a meta-regression. Am Heart J. 2005;149:504-11.
4.
go back to reference Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents: a hierarchical ayesian meta-analysis. Ann Intern Med. 2003;138:777-86. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents: a hierarchical ayesian meta-analysis. Ann Intern Med. 2003;138:777-86.
5.
go back to reference Daemen J, Boersma E, Flather M, Booth J, Stables R, Rodriguez A, et al. Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient level data from the ARTS, ERACI-II, MASS-II, and SoS trials. Circulation. 2008;118:1146-54. Daemen J, Boersma E, Flather M, Booth J, Stables R, Rodriguez A, et al. Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient level data from the ARTS, ERACI-II, MASS-II, and SoS trials. Circulation. 2008;118:1146-54.
6.
go back to reference Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, et al. Outcomes associated with drug-eluting and bare metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937-48. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, et al. Outcomes associated with drug-eluting and bare metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937-48.
7.
go back to reference Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006;119:1056-61. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006;119:1056-61.
8.
go back to reference Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202.
9.
go back to reference Filion KB, Roy AM, Baboushkin T, Rinfret S, Eisenberg MJ. Cost-effectiveness of drug-eluting stents including the economic impact of late stent thrombosis. Am J Cardiol. 2009;103:345-9. Filion KB, Roy AM, Baboushkin T, Rinfret S, Eisenberg MJ. Cost-effectiveness of drug-eluting stents including the economic impact of late stent thrombosis. Am J Cardiol. 2009;103:345-9.
10.
go back to reference Sangiorgi G, Melzi G, Agostoni P, Cola C, Clementi F, Romitelli P, et al. Engineering aspects of stents design and their translation into clinical practice. Ann Ist Super Sanita. 2007;43:89-100. Sangiorgi G, Melzi G, Agostoni P, Cola C, Clementi F, Romitelli P, et al. Engineering aspects of stents design and their translation into clinical practice. Ann Ist Super Sanita. 2007;43:89-100.
11.
go back to reference Hoffmann R, Mintz GS, Haager PK, Bozoglu T, Grube E, Gross M, et al. Relation of stent design and stent surface material to subsequent in-stent intimal hyperplasia in coronary arteries determined by intravascular ultrasound. Am J Cardiol. 2002;89:1360-4. Hoffmann R, Mintz GS, Haager PK, Bozoglu T, Grube E, Gross M, et al. Relation of stent design and stent surface material to subsequent in-stent intimal hyperplasia in coronary arteries determined by intravascular ultrasound. Am J Cardiol. 2002;89:1360-4.
12.
go back to reference Kastrati A, Dirschinger J, Boekstegers P, Elezi S, Schühlen H, Pache J, et al. Influence of stent design on 1-year outcome after coronary stent placement: a randomized comparison of five stent types in 1,147 unselected patients. Catheter Cardiovasc Interv. 2000;50:290-7. Kastrati A, Dirschinger J, Boekstegers P, Elezi S, Schühlen H, Pache J, et al. Influence of stent design on 1-year outcome after coronary stent placement: a randomized comparison of five stent types in 1,147 unselected patients. Catheter Cardiovasc Interv. 2000;50:290-7.
13.
go back to reference Briguori C, Sarais C, Pagnotta P, Liistro F, Montorfano M, Chieffo A, et al. In-stent restenosis in small coronary arteries: impact of strut thickness. J Am Coll Cardiol. 2002;40:403-9. Briguori C, Sarais C, Pagnotta P, Liistro F, Montorfano M, Chieffo A, et al. In-stent restenosis in small coronary arteries: impact of strut thickness. J Am Coll Cardiol. 2002;40:403-9.
14.
go back to reference Kastrati A, Mehilli J, .Dirschinger J, Dotzer F, Schunhlen H, Neumann FJ, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR STEREO) trial. Circulation. 2001;103:2816-21. Kastrati A, Mehilli J, .Dirschinger J, Dotzer F, Schunhlen H, Neumann FJ, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR STEREO) trial. Circulation. 2001;103:2816-21.
15.
go back to reference Pache J, Kastrati A, Mehilli J, Schunhlen H, Dotzer F, Hausleiter J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol. 2003;41:1283-8. Pache J, Kastrati A, Mehilli J, Schunhlen H, Dotzer F, Hausleiter J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol. 2003;41:1283-8.
16.
go back to reference Rittersma SZ, de Winter RJ, Koch KT, Bax M, Schotborgh CE, Mulder KJ, et al. Impact of strut thickness on late luminal loss after coronary artery stent placement. Am J Cardiol. 2004;93:477-80. Rittersma SZ, de Winter RJ, Koch KT, Bax M, Schotborgh CE, Mulder KJ, et al. Impact of strut thickness on late luminal loss after coronary artery stent placement. Am J Cardiol. 2004;93:477-80.
17.
go back to reference Kereiakes DJ, Cox DA, Hermiller JB, Midei MG, Bachinsky WB, Nukta ED, et al; Guidant Multi-Link Vision Stent Registry Investigators. Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol. 2003;92:463-6. Kereiakes DJ, Cox DA, Hermiller JB, Midei MG, Bachinsky WB, Nukta ED, et al; Guidant Multi-Link Vision Stent Registry Investigators. Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol. 2003;92:463-6.
18.
go back to reference de Man FH, Stella PR, Nathoe H, Kirkels H, Hamer B, Meijburg HW, et al. Stent thrombosis in real-world patients: a comparison of drug-eluting with bare metal stents. Neth Heart J. 2007;15:382-6. de Man FH, Stella PR, Nathoe H, Kirkels H, Hamer B, Meijburg HW, et al. Stent thrombosis in real-world patients: a comparison of drug-eluting with bare metal stents. Neth Heart J. 2007;15:382-6.
19.
go back to reference Product specifications Skylor stent system. Available at www.invatec.com/tool/home.php?s=0,1,55,56,98. Access: 5 February 2009. Product specifications Skylor stent system. Available at www.invatec.com/tool/home.php?s=0,1,55,56,98. Access: 5 February 2009.
20.
go back to reference Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, Es GA, et al, on behalf of the Academic Research Consortium. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation. 2007;115:2344-51. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, Es GA, et al, on behalf of the Academic Research Consortium. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation. 2007;115:2344-51.
21.
go back to reference Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2001;103:192-5. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2001;103:192-5.
22.
go back to reference Collet JP, Montalescot G, Blanchet B, Tanguy ML, Golmard JL, Choussat R, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation. 2004;100:2361-7. Collet JP, Montalescot G, Blanchet B, Tanguy ML, Golmard JL, Choussat R, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation. 2004;100:2361-7.
23.
go back to reference Diner AC, Bogousslavsky J, Brass LM. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331-7. Diner AC, Bogousslavsky J, Brass LM. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331-7.
24.
go back to reference Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-30. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-30.
25.
go back to reference Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, Clavijo LC, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006;113: 1108-13. Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, Clavijo LC, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006;113: 1108-13.
26.
go back to reference Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667-78. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667-78.
27.
go back to reference Quizhpe AR, Feres F, de Ribamar Costa J Jr, Abizaid A, Maldonado G, Costa R, Abizaid A, Cano M, Moreira AC, Staico R, Mattos LA, Tanajura LF, Chaves A, Centemero M, Sousa AM, Sousa JE. Drug-eluting stents vs. bare metal stents for the treatment of large coronary vessels. Am Heart J 2007;154:373-378. Quizhpe AR, Feres F, de Ribamar Costa J Jr, Abizaid A, Maldonado G, Costa R, Abizaid A, Cano M, Moreira AC, Staico R, Mattos LA, Tanajura LF, Chaves A, Centemero M, Sousa AM, Sousa JE. Drug-eluting stents vs. bare metal stents for the treatment of large coronary vessels. Am Heart J 2007;154:373-378.
28.
go back to reference Pfisterer M, Brunner-La Rocca HP, Rickenbacher P, Hunziker P, Mueller C, Nietlispach F, et al; BASKET. Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. Eur Heart J. 2009;30:16-24. Pfisterer M, Brunner-La Rocca HP, Rickenbacher P, Hunziker P, Mueller C, Nietlispach F, et al; BASKET. Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. Eur Heart J. 2009;30:16-24.
29.
go back to reference Pache J, Dibra A, Mehilli J, Dirschinger J, Schömig A, Kastrati A. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. Eur Heart J. 2005;26:1262-8. Pache J, Dibra A, Mehilli J, Dirschinger J, Schömig A, Kastrati A. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. Eur Heart J. 2005;26:1262-8.
30.
go back to reference Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, et al. Randomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularization. Catheter Cardiovasc Interv. 2007;69:790-8. Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, et al. Randomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularization. Catheter Cardiovasc Interv. 2007;69:790-8.
31.
go back to reference Daemen J, Tanimoto S, García-García HM, Kukreja N, van de Sande M, Sianos G, et al. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). Am J Cardiol. 2007; 99:1027-32. Daemen J, Tanimoto S, García-García HM, Kukreja N, van de Sande M, Sianos G, et al. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). Am J Cardiol. 2007; 99:1027-32.
32.
go back to reference Steg PG, Fox KA, Eagle KA, Furman M, Van de Werf F, Montalescot G, et al.; Global Registry of Acute Coronary Events (GRACE) Investigators. Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. Eur Heart J. 2009;30: 321-9. Steg PG, Fox KA, Eagle KA, Furman M, Van de Werf F, Montalescot G, et al.; Global Registry of Acute Coronary Events (GRACE) Investigators. Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. Eur Heart J. 2009;30: 321-9.
33.
go back to reference Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart. J 2007;28:2706-13. Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart. J 2007;28:2706-13.
34.
go back to reference Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F, et al.; DELAYED RRISC (Death and Events at Long-term follow-up AnalYsis: Extended Duration of the Reduction of Restenosis In Saphenous vein grafts with Cypher stent) Investigators. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol. 2007;50:261-7. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F, et al.; DELAYED RRISC (Death and Events at Long-term follow-up AnalYsis: Extended Duration of the Reduction of Restenosis In Saphenous vein grafts with Cypher stent) Investigators. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol. 2007;50:261-7.
35.
go back to reference Sketch MH Jr, Ball M, Rutherford B, Popma JJ, Russell C, Kereiakes DJ; Driver investigators. Evaluation of the Medtronic (Driver) cobalt-chromium alloy coronary stent system. Am J Cardiol. 2005;95:8-12. Sketch MH Jr, Ball M, Rutherford B, Popma JJ, Russell C, Kereiakes DJ; Driver investigators. Evaluation of the Medtronic (Driver) cobalt-chromium alloy coronary stent system. Am J Cardiol. 2005;95:8-12.
36.
go back to reference Legrand V, Kelbaek H, Hauptmann KE, Glogar D, Rutsch W, Grollier G, et al.; CLASS Investigators. Clinical and angiographic analysis with a cobalt alloy coronary stent (driver) in stable and unstable angina pectoris. Am J Cardiol. 2006;97:349-52. Legrand V, Kelbaek H, Hauptmann KE, Glogar D, Rutsch W, Grollier G, et al.; CLASS Investigators. Clinical and angiographic analysis with a cobalt alloy coronary stent (driver) in stable and unstable angina pectoris. Am J Cardiol. 2006;97:349-52.
37.
go back to reference Strehblow C, Gyöngyösi M, Zenker G, Wallner H, Heigert M, Siostrzonek P, et al.. Small vessel stenting with cobalt-chromium stents (Arthos Pico) in a real world setting. Coron Artery Dis. 2007;18:305-11. Strehblow C, Gyöngyösi M, Zenker G, Wallner H, Heigert M, Siostrzonek P, et al.. Small vessel stenting with cobalt-chromium stents (Arthos Pico) in a real world setting. Coron Artery Dis. 2007;18:305-11.
38.
go back to reference Burzotta F, Trani C, Todaro D, Mazzari MA, Porto I, De Vita MR, et al. Outcome of patients treated by a novel thin-strut cobalt-chromium stent in the drug-eluting stent era: Results of the SKICE (Skylor in real world practICE) registry. Cathet Cardiovasc Interv. 2009;73:457-65. Burzotta F, Trani C, Todaro D, Mazzari MA, Porto I, De Vita MR, et al. Outcome of patients treated by a novel thin-strut cobalt-chromium stent in the drug-eluting stent era: Results of the SKICE (Skylor in real world practICE) registry. Cathet Cardiovasc Interv. 2009;73:457-65.
39.
go back to reference Pfisterer M, Bertel O, Bonetti PO, Brunner-La Rocca HP, Eberli FR, Erne P, et al.; BASKET-PROVE Investigators. Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design. Am Heart J. 2008;155:609-14. Pfisterer M, Bertel O, Bonetti PO, Brunner-La Rocca HP, Eberli FR, Erne P, et al.; BASKET-PROVE Investigators. Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design. Am Heart J. 2008;155:609-14.
40.
go back to reference Kereiakes DJ, Kuntz RE, Mauri L, Krucoff MW. Surrogates, substudies, and real clinical end points in trials of drug-eluting stents. J Am Coll Cardiol. 2005;45:1206-12. Kereiakes DJ, Kuntz RE, Mauri L, Krucoff MW. Surrogates, substudies, and real clinical end points in trials of drug-eluting stents. J Am Coll Cardiol. 2005;45:1206-12.
Metagegevens
Titel
One-year clinical follow-up of a registry evaluating a percutaneous revascularisation strategy combining a pre-specified simple selection process with the use of a new thin-strut bare cobalt-chromium stent
Auteurs
P. R. Stella
G. Pavlakis
P. Agostoni
H. M. Nathoe
S. Hoseyni Guyomi
B. J. Hamer
T. X. Wildbergh
P. A. Doevendans
E. Van Belle
Publicatiedatum
01-10-2010
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Netherlands Heart Journal / Uitgave 10/2010
Print ISSN: 1568-5888
Elektronisch ISSN: 1876-6250
DOI
https://doi.org/10.1007/BF03091820